Lilly to invest $1 billion+ in new contract manufacturing in India

Investment to expand manufacturing and global medicine supply capacity

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines

Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines

Eli Lilly appoints Dr. Vivek Jha as Senior Director – Commercial Strategy, AI & Transformation

He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation

Lilly's Verzenio scores first OS improvement in breast Cancer

Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit